News for BLMS Stock

Bloomios Reports Q2 2023 Financial Results Bloomios Appoints Kevin Henry as National Sales Director Bloomios Reports Q1 2023 Revenue up 30% Sequentially and 84% Y/Y to $2.75 Million Bloomios Appoints Industry Veteran, Joe Reid, as Chief Manufacturing Officer Upexi Announces Sale of Select CBD Assets for $23.5 Million Bloomios to Develop and Produce New Range of Private-Label Products Utilizing, Ashwagandha, Melatonin, Kratom, Lion's Mane, Valerian Root, Reishi Mushroom and other Natural Ingredients Bloomios to Present at the 2022 LD Micro Invitational June 7-9 Bloomios Expands Production Capacity by 300%, Setting Stage for Strong Growth in 2022 Bloomios Reports 2021 Revenue at Record $8.5 Million, up from $1.3 Million in 2020 Bloomios Engages CMA to Lead New Investor and Public Relations Campaign Bloomios Begins Trading on OTCQB Venture Market as BLMS, as Hemp-Derived Cannabinoid Product Sales Exceed $8 million Bloomios Announces its' Form S-1 Registration Effective Allowing the Company to Raise up to $6.5 Million in Growth Capital Bloomios Shareholder Update & Growth Strategy